Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15420/icr.2017:4:2 http://scihub22266oqcxt.onion/10.15420/icr.2017:4:2 C5808481!5808481!29588735     free     free     free Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 215.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Interv+Cardiol 2017 ; 12 (2): 85-91 Nephropedia Template TP {{tp|p=29588735|t=2017. Current State of the Art in Approaches to Saphenous Vein Graft Interventions |pdf=|usr=}}{{29588735}} gab.com Text Current State of the Art in Approaches to Saphenous Vein Graft Interventions JO: Interv Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=29588735 #FOAvip Saphenous vein grafts (SVGs), used during coronary artery bypass graft surgery for severe coronary artery disease, are prone to degeneration and occlusion, leading to poor long-term patency compared with arterial grafts. Interventions used to treat SVG disease are susceptible to high rates of periprocedural MI and no-reflow. To minimise complications seen with these interventions, proper stents, embolic protection devices (EPDs) and pharmacological selection are crucial. Regarding stent selection, evidence has demonstrated superiority of drug-eluting stents over bare-metal stents in SVG intervention. The ACCF/AHA/SCA American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions guidelines recommend the use of EPDs during SVG intervention to decrease the risk of periprocedural MI, distal embolisation and no-reflow. The optimal pharmacological treatment for slow or no-reflow remains unclear, but various vasodilators show promise. Twit Text FOAVip Current State of the Art in Approaches to Saphenous Vein Graft Interventions ????Interv Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=29588735 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29588735 #FOAvip English Wikipedia <ref>{{Cite pmid|29588735}}</ref> Current State of the Art in Approaches to Saphenous Vein Graft Interventions #MMPMID29588735 Lee M; Kong J Interv Cardiol 2017[Sep]; 12 (2): 85-91 PMID29588735show ga Saphenous vein grafts (SVGs), used during coronary artery bypass graft surgery for severe coronary artery disease, are prone to degeneration and occlusion, leading to poor long-term patency compared with arterial grafts. Interventions used to treat SVG disease are susceptible to high rates of periprocedural MI and no-reflow. To minimise complications seen with these interventions, proper stents, embolic protection devices (EPDs) and pharmacological selection are crucial. Regarding stent selection, evidence has demonstrated superiority of drug-eluting stents over bare-metal stents in SVG intervention. The ACCF/AHA/SCA American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions guidelines recommend the use of EPDs during SVG intervention to decrease the risk of periprocedural MI, distal embolisation and no-reflow. The optimal pharmacological treatment for slow or no-reflow remains unclear, but various vasodilators show promise. äCurrent State of the Art in Approaches to Saphenous Vein Graft Interve(epmc).pdf DeepDyve Pubget Overpricing